Skip to content
All Sections
Subscribe Now
79°F
Sunday, August 18th 2024
Today's E-Edition
Home Page
Close Menu
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
SUBSCRIBE NOW
Close Menu
Morning Report in your inbox!
Sign Up
Subscribe
Account Settings
Contact Us
Log Out
Spoof a user
Morning Report in your inbox!
Sign Up
Subscribe
Search
Silicon Valley
79°F
Sunday, August 18th 2024
Today's E-Edition
Business
Technology
Commercial Real Estate
Housing
Marketplace
The Mercury News
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Humanigen, Inc.
Humanigen Reports Second Quarter 2022 Financial Results
August 12, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Receives Preliminary Topline Data From NIH/NIAID Study of Lenzilumab in ACTIV-5/BET-B
July 12, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Peer-Reviewed Publication in Thorax Supporting Early Treatment of Hospitalized COVID-19 Patients with Lenzilumab Guided by C-Reactive Protein
July 06, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
NIH/NIAID Locks ACTIV-5/BET-B Database
June 30, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Enters into Agreement with PCI Pharma Services as Part of Preparations for Commercialization in the United Kingdom
June 16, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Participation and Presentation at Multiple Conferences in June
June 03, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Participation and Presentation at H.C. Wainwright Global Investment Conference
May 24, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Reports First Quarter 2022 Financial Results
May 05, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Participation and Presentation at Multiple Conferences in May
May 04, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
GM-CSF Knock-out CAR-T Study Published in Peer-Reviewed Journal Leukemia
April 20, 2022
From
Humanigen, Inc.
Via
Business Wire
Humanigen Announces Peer-Reviewed Publication Demonstrating the Potential Clinical and Economic Benefits of Lenzilumab from the Perspective of the NHS
April 19, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen to Present and Participate at Multiple Investor Events in March
February 25, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen to Present at BIO CEO & Investor Conference
February 11, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Launches Managed Access Program for Lenzilumab
February 09, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen and Cenexi Announce Collaboration to Manufacture Lenzilumab in France
February 08, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Peer-Reviewed Publication in The Journal of Medical Economics Demonstrating the Clinical and Economic Benefits of Lenzilumab
January 18, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Aligns with FDA on Potential Registration Phase 3 Study for Lenzilumab with CAR-T
January 10, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Target Enrollment in Phase 2/3 ACTIV-5/BET-B Trial of Lenzilumab for the Treatment of COVID-19 has Been Achieved
January 05, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen to Present at Investor Conferences January 7 and 13, 2022
January 04, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Lenzilumab Treatment Response in Hospitalized COVID-19 Patients Correlates with C-Reactive Protein Levels
January 03, 2022
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Presentation at 40th Annual J.P. Morgan Healthcare Conference in January 2022
December 15, 2021
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Conference Call and Webcast to Discuss Lancet Respiratory Medicine Publications and Provide a Corporate Update
December 01, 2021
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
The Lancet Respiratory Medicine Publishes Peer-Reviewed Paper and Independent Expert Commentary on Positive Phase 3 Lenzilumab Results
December 01, 2021
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Abstracts Accepted for the British Thoracic Society Winter Meeting 2021
November 22, 2021
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Revised Time for Presentation at Jefferies London Healthcare Conference
November 16, 2021
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Reports Third Quarter and Nine Months Ending September 30, 2021 Financial Results and Provides Corporate Update
November 12, 2021
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease
November 11, 2021
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Release of Abstracts at ASH
November 05, 2021
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Humanigen Announces Participation and Presentation at Multiple Conferences in November
November 02, 2021
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
European Commission Selects Humanigen’s Lenzilumab as One of the 10 Most Promising Treatments for COVID-19
October 26, 2021
From
Humanigen, Inc.
Via
Business Wire
Tickers
HGEN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
Close